CJC1295(withoutDAC)5MG+1PA5MG

Price range: $100.00 through $120.00

10vials/price

Clear

SKU: N/A Category: Peptide For Sale

Specifications

CAS: CJC-1295: 863288-34-0 Ipamorelin: 170851-70-4
Chemical Formula: CJC-1295 No DAC: C₁₅₂H₂₅₂N₄₄O₄₂ Ipamorelin: C₃₈H₄₉N₉O₅
Molecular weight: Ipamorelin: 711.85296 g/mol MOD-GRF(1-29) CJC1295 No DAC: 33367.954 g/mol
Peptide Sequence: Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 MOD-GRF(1-29) CJC-1295 No DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Synonyms: Ipamorelin Acetate, IPAM, NNC-26-0161 MOD-GRF(1-29), CJC-1295 without DAC, modgrf
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

CJC-1295 without DAC 5mg + IPA 5mg – About This Product

This combination is studied to examine how growth hormone secretion is stimulated through two distinct signaling pathways:

CJC-1295 without DAC: Acts as a GHRH receptor agonist, activating adenylyl cyclase and cAMP-dependent pathways on pituitary somatotrophs
Ipamorelin: Acts as a GHRP-receptor agonist (GHS-R agonist) through calcium-dependent signaling mechanisms, demonstrating selectivity for GH release without affecting ACTH or cortisol levels

The synergistic combination leverages complementary mechanisms: cAMP activation (CJC-1295) and calcium-dependent signaling (Ipamorelin) to produce amplified GH secretion through multi-pathway activation.

CJC-1295 without DAC 5mg + IPA 5mg – Key Features and Benefits

High-purity peptides provided in separate 5 mg vials for precise dosing in research.
Lyophilized powder form for enhanced stability and easy reconstitution.
Synergistic Functionality: Combines two peptides that stimulate growth hormone through different receptors.
Metabolic Regulation: Used in studies exploring endogenous growth hormone stimulation.
Cellular Impact: Supports research on tissue repair, cell regeneration, and recovery.
Stable when stored correctly at low temperatures.

CJC-1295 without DAC 5mg + IPA 5mg – Mechanism & Research Applications

This combination is used to study how growth hormone secretion is stimulated through two distinct pathways. CJC-1295 acts like GHRH, while Ipamorelin activates ghrelin receptors.

Research explores the peptides’ roles in metabolic regulation, tissue growth, and endocrine modulation, with a focus on muscle and bone biology and potential applications in aging-related processes.

CJC-1295 without DAC 5mg + IPA 5mg – Dosing & Observed Effects in Research

In preclinical and laboratory studies, dosing protocols for CJC-1295 without DAC and Ipamorelin combinations typically employ:

CJC-1295 without DAC: 100–300 mcg per injection, administered 2–3 times daily to maintain elevated GH levels (short 30-minute half-life)
Ipamorelin: 200–300 mcg per injection, administered daily or 2–3 times daily depending on study protocol
Combination approach: Both peptides are often co-administered to maximize synergistic GH release through dual-pathway activation

Published single-dose rodent studies have evaluated CJC-1295 at 30–60 µg/kg; however, sustained research applications typically use the absolute dosages listed above.

Research observations include:

Elevated growth hormone (GH) levels with enhanced pulsatility
Increased insulin-like growth factor 1 (IGF-1) production
Enhanced tissue repair and recovery markers
Preserved hormone selectivity (ipamorelin does not increase ACTH or cortisol)

These observations are based on animal studies, and there is no clinical data on human dosing or safety/efficacy.

CJC-1295 without DAC 5mg + IPA 5mg – Storage, Safety

Storage: Store lyophilized peptides at –20°C or below in a dry, light-protected
After reconstitution, store at 2–8°C and use within 5–7 days.
Avoid freeze-thaw cycles to protect peptide integrity.
Handle using aseptic techniques and proper laboratory safety protocols.